Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Subsidiary To Apply For Japan Approval of Intelence AIDS Drug

This article was originally published in PharmAsia News

Executive Summary

Janssen Pharmaceutical says it plans to apply for Japanese approval of its TMC125 (etravine) anti-retroviral for treating AIDS. The drug is sold in the United States as Intelence by Janssen's parent, Johnson & Johnson. If approved, it would be one of only a few of its type marketed in Japan. Janssen plans to apply to market the drug as a treatment for HIV patients resistant to other drugs or who have experienced a resurgence of the virus after treatment with other drugs. In the future, Janssen plans to get TMC125 approved as a first-choice combination treatment. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts